Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.83% and ...

FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.

Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Chip stocks advanced, led by Broadcom ( AVGO) after UBS analysts raised their price target for the stock, citing the ...

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...

The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the ...

The deal will open the door for the company to tap into an archive of more than 2,000 designs by Key West Hand Print Fabrics ...

The Japanese c ...